Disease index

treatment-resistant depression

Mental health · 2021–2024

4decisions
1medicine
4carried consumer input
84individual submissions

Every decision

MedicineMeetingOutcomeConsumer input
esketamine Treatment of treatment-resistant depression (TRD) in adults with major depressive disorder who have not responded adequately to at least two separate courses… Dec 2024 Deferred 2 individuals
esketamine Treatment of adult patients with treatment-resistant depression (major depressive disorder who have not responded adequately to at least 2 separate courses of… Jul 2023 Not recommended 58 individuals
esketamine Treatment-resistant depression (TRD) in adult patients with major depressive disorder who have not responded adequately to at least two separate courses of… Jul 2022 Not recommended 22 individuals Lived Experience Australia · Samy Medical Group
esketamine Treatment of treatment-resistant depression (TRD) in adults who have not responded adequately to at least two different antidepressants of adequate dose and… Jul 2021 Not recommended 2 individuals

Who spoke

Lived Experience Australia · Samy Medical Group

What the PBS pays

$3M in government benefit over 2024–25, across 630 services.

This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.

MedicineGovernment benefit
esketamine $2.6M

Appraised elsewhere

NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.

TechnologyAppraisalOutcomeDate
esketamine nasal sprayEsketamine nasal spray for treatment-resistant depression TA854 unknown 2022-12

Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.